Watch IRMD. Know when insiders buy.
One email the day a filing lands. Free.
IRMD
IRADIMED CORP
84.40
+0.95 +1.14%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · insiders 44, shorts 30
Insiders, 90 days
−$123K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1BP/E 47.2DIV YIELD —FCF YIELD 2.33%REV TTM $86.3M +11.2%NET INCOME $23.1M +11.6%NET CASH —52W 68.55 – 105.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $20.5M | +0.3% | 74.1% | $6.4M | $5.2M | −9.6% | 0.41 | $5.9M | $185K | $5.8M | Jul 31 |
| Q1 2026 · Mar 31 | $22M | +12.6% | 76.5% | $7.2M | $5.8M | +24.1% | 0.45 | $8.3M | $403K | $7.9M | Jul 31 |
| Q4 2025 · Dec 31derived | $22.7M | +17.0% | 75.1% | $7.1M | $6.4M | +25.2% | 0.50 | $5.9M | $294K | $5.6M | Mar 6 |
| Q3 2025 · Sep 30 | $21.2M | +15.7% | 77.8% | $6.8M | $5.6M | +10.4% | 0.43 | $7M | $1.1M | $5.8M | Nov 3 |
| Q2 2025 · Jun 30 | $20.4M | +13.8% | 78.2% | $6.8M | $5.8M | +17.8% | 0.45 | $7.7M | $2.6M | $5.1M | Jul 31 |
| Q1 2025 · Mar 31 | $19.5M | +10.9% | 76.1% | $5.4M | $4.7M | +13.3% | 0.37 | $4.3M | $3.7M | $595K | Jul 31 |
| Q4 2024 · Dec 31derived | $19.4M | +11.1% | 76.1% | $5.8M | $5.1M | +13.4% | 0.40 | $6M | $2.8M | $3.2M | Mar 6 |
| Q3 2024 · Sep 30 | $18.3M | +11.0% | 77.4% | $5.8M | $5M | −0.3% | 0.40 | $9.1M | $3.8M | $5.3M | Nov 3 |
| Q2 2024 · Jun 30 | $17.9M | — | 78.1% | $5.6M | $4.9M | — | 0.38 | $6.6M | $1.1M | $5.5M | Nov 3 |
| Q1 2024 · Mar 31 | $17.6M | — | 76.1% | $4.7M | $4.1M | — | 0.32 | $3.9M | $271K | $3.6M | Nov 3 |
| Q4 2023 · Dec 31derived | $17.5M | — | 76.9% | $5.2M | $4.5M | — | 0.36 | $3.9M | $532K | $3.4M | Sep 3 |
| Q3 2023 · Sep 30 | $16.5M | — | 77.8% | $5.9M | $5.1M | — | 0.40 | $1.4M | $308K | $1.1M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $83.8M | 76.7% | $26.1M | $22.5M | 26.8% | 1.75 | $24.9M | $7.8M | $17.2M | — | $15M |
| FY2024 · to Dec 31 | $73.2M | 76.9% | $22M | $19.2M | 26.3% | 1.50 | $25.6M | $8M | $17.6M | — | $13.7M |
| FY2023 · to Dec 31 | $65.6M | 76.5% | $20M | $17.2M | 26.2% | 1.35 | $13.5M | $7.4M | $6M | — | $13.2M |
| FY2022 · to Dec 31 | $53.3M | 77.4% | $15.6M | $12.8M | 24.1% | 1.02 | $10M | $823K | $9.2M | — | $12.6M |
| FY2021 · to Dec 31 | $41.8M | 76.6% | $9.8M | $9.3M | 22.3% | 0.74 | $11.3M | $482K | $10.8M | — | — |
| FY2020 · to Dec 31 | $31.7M | 74.3% | −$756K | $1.4M | 4.3% | 0.11 | $5.8M | $443K | $5.4M | — | — |
Every number comes from IRADIMED CORP's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.